Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Embree-Ku, M.
Right arrow Articles by Boekelheide, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Embree-Ku, M.
Right arrow Articles by Boekelheide, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

FasL Deficiency Enhances the Development of Tumors in p53+/- Mice

Michelle Embree-Ku

Department of Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island 02912

Kim Boekelheide

Department of Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island 02912, Kim Boekelheide{at}Brown.edu

In the multistep process of tumor development, several events occur to transform cells from normal to malignant. Although p53 is one of the most commonly mutated genes in a wide variety of tumors, how other genes interact with p53 to transform cells is only just beginning to be understood. To study the effects of the interaction of the Fas system with p53 in tumor progression and development, mice with a targeted disruption of the p53 tumor supressor gene and a mutation in Fas ligand were bred. Organ weights, life expectancy, and tumor and tissue histology were assessed. Although spleen weights were drastically increased in FasL-/-p53-/- mice, the FasL deficiency had no effect on life expectancy or the tumor spectrum of homozygous p53-deficient mice. The FasL deficiency reduced the median time to death from 12.1 months in FasL+/+ p53+ /- mice to 9.6 months in FasL-/- p53 +/- mice, and led to a shift in tumor spectrum from predominantly sarcomas (63%) when FasL was present to a large number of lymphomas (76%) in FasL-/-p53+/- mice. Given the reduced life span and increased incidence of lymphoma in FasL -/- p53+/- mice, these mice could be useful in carcinogenicity testing, particularly for understanding mechanisms of compounds that are nongenotoxic.

Key Words: Tumor • apoptosis • p53 • Fas • lymphoma • sarcoma • gld.

References

  • Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui S., Wilson CB, McConahey PJ, Murphy ED, Roths JB, Dixon FJ (1978). Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 148: 1198—1215.[Abstract/Free Full Text]
  • Bellgrau D., Gold D., Selawry H., Moore J., Franzusoff A., Duke RC ( 1995). A role for CD95 ligand in preventin g graft rejection. Nature 377: 630—632.[CrossRef][Medline] [Order article via Infotrieve]
  • Bennett M., Macdonald K., Chan SW, Luzio JP, Simari R., Weissberg P. (1998). Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis. Science 282: 290—293.[Abstract/Free Full Text]
  • Blanchard KT, Barthel C., French JE, Holden HE, Moretz R., Pack FD, Tennant RW, Stoll RE (1999). Transponder-induce d sarcoma in the heterozygous p53+/- mouse. Toxicol Pathol 27: 519—527.[Abstract/Free Full Text]
  • Chervonsky AV, Wang Y., Wong FS, Visintin I., Flavell RA, Janeway CA Jr, Matis LA (1997). The role of Fas in autoimmune diabetes. Cell 89: 17—24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cohen PL, Eisenberg RA (1991). Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9: 243—269.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Davidson WF, Giese T., Fredrickson TN (1998). Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 187: 1825—1838.[Abstract/Free Full Text]
  • Donehower LA, Harvey M., Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215—221.[CrossRef][Medline] [Order article via Infotrieve]
  • Donehower LA (1996). The p53-deficient mouse: A model for basic and applied cancer studies. Semin Cancer Biol 7: 269—278.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Embree-Ku ME, Venturini D., Boekelheide K. (2002). Fas is involved in the p53-dependent apoptotic response to ionizing radiation in mouse testis. Biol Reprod, 66: 1456—1461.[Abstract/Free Full Text]
  • Friedman PN, Chen X., Bargonetti J., Prives C. (1993). The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci USA 90: 3319—3323.[Abstract/Free Full Text]
  • Galle PR, Hofmann WJ, Walczak H., Schaller H., Otto G., Stremmel W., Krammer PH, Runkel L. (1995). Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182: 1223—1230.[Abstract/Free Full Text]
  • Giordano C., Stassi G., De Maria R., Todaro M., Richiusa P., Papoff G., Ruberti G., Bagnasco M., Testi R., Galluzzo A. (1997). Potential involvement of Fas and its ligand in the pathogenesi s of Hashimoto's thyroiditis. Science 275: 960—963.[Abstract/Free Full Text]
  • Griffith TS, Brunner T., Fletcher SM, Green DR, Ferguson TA (1995). Fas ligand-induce d apoptosis as a mechanism of immune privilege. Science 270: 1189—1192.[Abstract/Free Full Text]
  • Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French LE, Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J., Tschopp J. (1996). Melanoma cell expression of Fas(Apo-1/CD95 ) ligand: Implications for tumor immune escape. Science 274: 1363—1366.[Abstract/Free Full Text]
  • Harvey M., McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A., Donehower LA (1993). Spontaneous and carcinogen-induce d tumorigenesis in p53-deficient mice. Nat Genet 5: 225—229.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Howes KA, Ransom N., Papermaster DS, Lasudry JG, Albert DM, Windle JJ (1994). Apoptosis or retinoblastoma: Alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev 8: 1300—1310.[Abstract/Free Full Text]
  • Itoh N., Imagawa A., Hanafusa T., Waguri M., Yamamoto K., Iwahashi H., Moriwaki M., Nakajima H., Miyagawa J., Namba M., Makino S., Nagata S., Kono N., Matsuzawa Y. (1997). Requirement of Fas for the development of autoimmune diabetes in nonobes e diabetic mice. J Exp Med 186: 613—618.[Abstract/Free Full Text]
  • Jacks T., Remington L., Williams BO, Schmitt EM, Halachmi S., Bronson RT, Weinberg RA (1994). Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1—7.[Medline] [Order article via Infotrieve]
  • Kaplan D., Sieg S. ( 1998). Role of the Fas/Fas ligand apoptotic pathway in human immunodeficiency virus type 1 disease. J Virol 72: 6279—6282.[Free Full Text]
  • Knudson AG Jr (1971) Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820—823.[Abstract/Free Full Text]
  • Lynch DH, Watson ML, Alderson MR, Baum PR, Miller RE, Tough T., Gibson M., Davis-Smith M., Smith CA, Hunter K., Bhat D., Din W., Goodwin G., Seldin MF (1994). The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1: 131—136.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McClatchey AI, Saotome I., Mercer K., Crowley D., Gusella JF, Bronson RT, Jacks T. (1998). Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 12: 1121—1133.[Abstract/Free Full Text]
  • Miyashita T., Reed JC ( 1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293—299.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mossman BT (1994). Carcinogenesis and related cell and tissue responses to asbestos: A review. Ann Occup Hyg 38: 617—624, 423.
  • Nagata S., Golstein P. (1995). The Fas death factor. Science 267: 449—456.[Free Full Text]
  • O'Connell J., O'Sullivan GC, Collins JK, Shanahan F.( 1996). The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184: 1075—1082.[Abstract/Free Full Text]
  • Owen-Schaub L., Chan H., Cusack JC, Roth J., Hill LL (2000). Fas and Fas ligand interactions in malignant disease. Int J Oncol 17: 5—12.[Web of Science][Medline] [Order article via Infotrieve]
  • Peng SL, Robert ME, Hayday AC, Craft J. (1996). A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J Exp Med 184: 1149—1154.[Abstract/Free Full Text]
  • Purdie CA, Harrison DJ, Peter A., Dobbie L., White S., Howie SE, Salter DM, Bird CC, Wyllie AH, Hooper ML, Clarke AR ( 1994). Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9: 603—609.[Web of Science][Medline] [Order article via Infotrieve]
  • Roths JB, Murphy ED, Eicher EM (1984). A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med 159: 1—20.[Abstract/Free Full Text]
  • Schneider E., Moreau G., Arnould A., Vasseur F., Khodabaccus N., Dy M., Ezine S. (1999). Increased fetal and extramedullary hematopoiesis in Fasdeficient C57BL/6-lpr/lpr mice. Blood 94: 2613—2621.[Abstract/Free Full Text]
  • Sills RC, French JE, Cunningham ML (2001). New models for assessing carcinogenesis: An ongoing process. Toxicol Lett 120: 187—198.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sinn E., Muller W., Pattengale P., Tepler I., Wallace R., Leder P. (1987). Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 49: 465—475.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Symonds H., Krall L., Remington L., Saenz-Robles M., Lowe S., Jacks T., Van Dyke T. (1994). p53-dependent apoptosi s suppresses tumor growth and progression in vivo. Cell 78: 703—711.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Takahashi T., Tanaka M., Brannan CI, Jenkins NA, Copeland NG, Suda T., Nagata S. (1994). Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76: 969— 976.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Trauth BC, Klas C., Peters AM, Matzku S., Moller P., Falk W., Debatin KM, Krammer PH (1989). Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245: 301—305.[Abstract/Free Full Text]
  • Traver D., Akashi K., Weissman IL, Lagasse E. (1998). Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 9: 47—57.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Venkatachalam S., Shi YP, Jones SN, Vogel H., Bradley A., Pinkel D., Donehower LA (1998). Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation. EMBO J 17: 4657—4667.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ward JM, Tadesse-Heath L., Perkins SN, Chattopadhyay SK, Hursting SD, Morse HC 3rd (1999). Splenic marginal zone B-cell and thymic T-cell lymphomas in p53-deficient mice. Lab Invest 79: 3—14.[Web of Science][Medline] [Order article via Infotrieve]
  • Watanabe-Fukunaga R., Brannan CI, Copeland NG, Jenkins NA, Nagata S. (1992). Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314— 317.[CrossRef][Medline] [Order article via Infotrieve]
  • Zornig M., Grzeschiczek A., Kowalski MB, Hartmann KU, Moroy T. (1995). Loss of Fas/Apo-1 receptor accelerates lymphomagenesi s in E mu L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene 10: 2397—2401.[Web of Science][Medline] [Order article via Infotrieve]

Toxicologic Pathology, Vol. 30, No. 6, 705-713 (2002)
DOI: 10.1080/01926230290166797
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
Z. Saifudeen, S. Dipp, J. Stefkova, X. Yao, S. Lookabaugh, and S. S. El-Dahr
p53 Regulates Metanephric Development
J. Am. Soc. Nephrol., November 1, 2009; 20(11): 2328 - 2337.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Embree-Ku, M.
Right arrow Articles by Boekelheide, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Embree-Ku, M.
Right arrow Articles by Boekelheide, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?